Acasti Pharma Inc. (ACST)

Acasti Pharma Income Statement

Financials in millions CAD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	0	0	0	0	0.2	0
Cost of Revenue	0	0	0	0	0.08	0
Gross Profit	0	0	0	0	0.12	0
Selling, General & Admin	6.68	6.68	8.28	9.78	6.66	8.46
Research & Development	4.68	4.68	9.97	5.56	4.17	15.97
Other Operating Expenses	1.49	1.49	33.91	0.25	5.7	0
Operating Expenses	12.85	12.85	52.16	15.59	16.54	24.44
Operating Income	-12.85	-12.85	-52.16	-15.59	-16.42	-24.44
Interest Expense / Income	-0.91	-0.91	-0.25	0	0	1.08
Other Expense / Income	2.74	2.74	0.06	-5.12	3.26	-
Pretax Income	-14.69	-14.69	-51.97	-10.47	-19.68	-25.51
Income Tax	-1.83	-1.83	-9.54	-0.65	0	0
Net Income	-12.85	-12.85	-42.43	-9.82	-19.68	-25.51
Shares Outstanding (Basic)	10	10	7	6	2	2
Shares Outstanding (Diluted)	10	10	7	6	2	2
Shares Change	28.16%	28.16%	21.09%	148.46%	40.25%	55.80%
EPS (Basic)	-1.35	-1.35	-5.71	-1.62	-7.98	-14.40
EPS (Diluted)	-1.35	-1.35	-5.71	-1.62	-7.98	-14.40
Free Cash Flow	-12.24	-12.24	-15.93	-17.23	-14.39	-23.27
Free Cash Flow Per Share	-1.28	-1.28	-2.14	-2.81	-5.82	-13.21
Gross Margin	-	-	-	-	61.22%	-
Operating Margin	-	-	-	-	-8377.04%	-
Profit Margin	-	-	-	-	-10039.80%	-
Free Cash Flow Margin	-	-	-	-	-7340.82%	-
EBITDA	-15.59	-15.59	-52.09	-10.47	-18.75	-22.12
EBITDA Margin	-	-	-	-	-9568.37%	-
Depreciation & Amortization	0.01	0.01	0.12	0	0.92	2.32
EBIT	-15.6	-15.6	-52.22	-10.47	-19.68	-24.44
EBIT Margin	-	-	-	-	-10039.80%	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).